Benefits
Custom-developed panels
Users communicate their targets of interest, and we will develop ad-hoc detection panels.
![Artwork169_13da9c14-8788-42b9-8ba7-0b07053e4468](https://alitheagenomics.com/hubfs/Artwork169_13da9c14-8788-42b9-8ba7-0b07053e4468.png)
Up to
100
targets
Experimentally validated panels for differential expression analysis.
No prior RNA extraction needed
An optimized lysis buffer for RNA solubilization.
Minimal sequencing cost
By only sequencing the targets, sequencing costs are drastically decreased.
What we do
MERCURIUS ™
Targeted DRUG-seq service
The MERCURIUS™ Targeted DRUG-seq service offers the most comprehensive, high-throughput and cost-efficient solution for targeted gene expression analysis projects starting from 2D cell cultures.
As part of the Targeted DRUG-seq service, clients share their genes of interest with us, we develop a corresponding custom detection panel and validate it directly on their RNA samples.
As part of the Targeted DRUG-seq service, we send our clients a proprietary Cell Lysis Buffer which is optimized for both cell lysis and downstream enzymatic reactions, without having to perform RNA extraction in between.
After mixing the Lysis Buffer with their cells, the client can return their cell lysates to us to be used for panel validation.
Once the targeted gene panel validation is complete, we will inform the client that the dedicated service is correctly established and that we are ready to receive their test samples.
By combining the advantages of the targeted approach with the DRUG-seq system, up to 100 different genes can be assessed across tens to thousands of samples in parallel, significantly reducing the time and costs associated with library preparation and sequencing.
As a result of our service, our clients receive raw sequencing data (fastq files), gene count matrices and analysis reports files.
Optional downstream differential gene expression analysis are also available upon request.
![img_cell-lysate img_cell-lysate](https://alitheagenomics.com/hubfs/img_cell-lysate.jpeg)
How does it work
-
-
Alithea ships the Cell Lysis Buffer
-
-
Client ships the cell lysates to Alithea for targeted gene panel validation
-
4 to 8 weeks
Alithea develops and validates the custom detection panel on customer's samples - Client Checkpoint
-
-
2 days
MERCURIUS™ Targeted DRUG-seq library prep for Illumina and AVITI
-
1 week
Library QC - Client Checkpoint
(Qubit, Fragment analyzer) -
1.5 weeks
Sequencing - Illumina / AVITI
-
1 week
Data analysis and reporting - Client Checkpoint
-
Data
-
Optional: Alithea performs Differential Gene Expression analysis
FAQs
-
The recommended range of input material is in the range of 5’000-50’000 cells..
-
Targeted DRUG-seq is a 3’-end RNA sequencing method that requires significantly less sequencing than standard BRB-seq to achieve accurate gene quantification. Therefore, we recommend sequencing 100 reads per target for each sample, which enables reliable detection of the targeted genes.
-
As part of our standard service pipeline, we align the generated data to the genome of choice, provide a detailed report on the alignment and gene counting statistics and, finally, provide ready-to-use gene count matrices for downstream analysis.
Speak with our RNA sequencing experts
Need guidance or have questions about DRUG-seq and our service?
Easily book a call with our RNA-seq experts.